Breast cancer cells exhibit a non-linear proliferative dose response to progestins
| dc.contributor.advisor | McDonnell, Donald P | |
| dc.contributor.advisor | Murphy, Susan K | |
| dc.contributor.author | Dolan, Emma | |
| dc.date.accessioned | 2024-03-07T18:39:19Z | |
| dc.date.issued | 2023 | |
| dc.department | Pharmacology | |
| dc.description.abstract | The steroid hormone progesterone has complex physiologic effects. In typical development and function, cells respond to progesterone in a dose- and tissue-specific manner. Despite the wide range of physiologic concentrations, canonical effects of progesterone have been characterized in the context of a high physiologic dose (10nM+), relevant during uterine cycling. This narrow focus has produced a gap in knowledge, particularly as it relates to the effects of post-menopausal low concentration progestins (0.1-0.3nM). Given that healthy tissues possess regulatory mechanisms to sense and respond to progesterone in a non-linear dose-specific manner, we hypothesized that breast malignancies would also display discontinuous dose-specific dynamic responses. Our results show that treatment with low dose progestins (0.1-0.3nM) drives proliferation in T47D human breast cancer cells, while high dose progestins (10nM+) inhibit proliferation. Using both unbiased and targeted approaches, we found that low dose progestins facilitate cell cycle entry by enhanced expression of CCND1 (cyclin D1) and SGK1 (serum and glucocorticoid related kinase 1), which are required for initiation of the downstream molecular cascade including phosphorylation of retinoblastoma protein (Rb) and expression E2F1. Expression of CCND1 and SGK1 mRNA are proximal responses to low dose progestin treatment, but transcriptional activation is not mediated by canonical progesterone receptor (PR) activity. Future work is needed to identify previously unexplored mechanisms of PR action in the context of low dose progestin treatments. In summary, these results challenge the assumption of dose response linearity to progestins and show unique functional and molecular effects of low dose progestin treatment. Of potential concern, our findings suggest that certain breast cancers, especially those expressing high levels of PR, may be accelerated by normal post-menopausal circulating concentrations of progestins (0.1-0.3nM). However, these findings also offer a sound rationale for the clinical therapeutic use of high dose progestins for patients with PR+ breast cancer. | |
| dc.identifier.uri | ||
| dc.rights.uri | ||
| dc.subject | Pharmacology | |
| dc.subject | Molecular biology | |
| dc.subject | Breast cancer | |
| dc.subject | Progesterone | |
| dc.subject | Progesterone receptor | |
| dc.subject | Proliferation | |
| dc.subject | PROTAC | |
| dc.title | Breast cancer cells exhibit a non-linear proliferative dose response to progestins | |
| dc.type | Dissertation | |
| duke.embargo.months | 23 | |
| duke.embargo.release | 2026-02-07T18:39:19Z |